Axsome Therapeutics (AXSM) Non-Current Assets (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Non-Current Assets data on file, last reported at $102.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets changed 0.36% year-over-year to $102.4 million; the trailing twelve-month figure through Mar 2026 stood at $410.3 million (up 16.23% YoY), and the FY2025 full-year result was $100.8 million, up 20.84% from the prior year.
• Non-Current Assets rose to $102.4 million in Q1 2026, from $100.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $103.9 million in Q3 2025 to a low of $1.7 million in Q1 2022.
• A 5-year average of $85.2 million and a median of $85.8 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 6675.02% in 2022 and decreased 7.58% in 2024, its largest moves.
• Tracing AXSM's Non-Current Assets over 5 years: stood at $85.8 million in 2022, then fell by 2.17% to $84.0 million in 2023, then decreased by 0.64% to $83.4 million in 2024, then gained by 20.84% to $100.8 million in 2025, then rose by 1.57% to $102.4 million in 2026.
• Business Quant data shows AXSM's Non-Current Assets at $102.4 million in Q1 2026, $100.8 million in Q4 2025, and $103.9 million in Q3 2025.